Welcome to our dedicated page for Therapeuticsmd SEC filings (Ticker: TXMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The TherapeuticsMD, Inc. (TXMD) SEC filings page brings together the company’s official regulatory documents, which describe its status as a Nevada corporation with common stock listed on The Nasdaq Stock Market LLC under the symbol TXMD. Filings such as Form 8-K, the definitive proxy statement on Schedule 14A, and other periodic reports provide detailed information on the company’s financial condition, governance, and capital structure.
Recent Form 8-K filings furnished by TherapeuticsMD include disclosures of quarterly financial results, where the company reports net income or net loss from continuing operations, license revenues primarily associated with the Mayne License Agreement, and total operating expenses. These filings often incorporate press releases that explain how the company’s transition to a pharmaceutical royalty business and its focus on cost control affect its reported results.
The company’s definitive proxy statement outlines matters submitted to stockholders, including the election of directors, advisory votes on executive compensation, the ratification of the independent auditor, and proposals to amend the company’s Amended and Restated Articles of Incorporation to increase the number of authorized shares of common stock. Voting results for these proposals are reported in subsequent Form 8-K filings, which detail how stockholders voted on director elections, say-on-pay, say-on-frequency, auditor ratification, and share authorization changes.
On Stock Titan, TXMD filings are updated as they are made available through the SEC’s EDGAR system. Each filing can be reviewed in full, and AI-powered tools can help summarize key points, such as the outcomes of stockholder meetings, changes to authorized share capital, and the company’s reported financial performance. This allows users to quickly understand the main elements of TherapeuticsMD’s regulatory disclosures while retaining access to the complete original documents for deeper analysis.
TherapeuticsMD, Inc. has appointed Carr, Riggs & Ingram, L.L.C. (CRI) as its new independent registered public accounting firm, effective January 15, 2026. This change follows a transaction in which CRI acquired certain assets related to the capital markets practice of the prior auditor, Berkowitz Pollack Brant Advisors + CPAs (BPB), which has ceased serving as the company’s auditor.
BPB’s audit reports for the fiscal years ended December 31, 2024 and December 31, 2023 did not contain adverse opinions or disclaimers, but they did include an explanatory paragraph about uncertainty regarding the company’s ability to continue as a going concern. The company reports there were no disagreements or reportable events with BPB, and it states that neither it nor its representatives consulted with CRI on accounting or auditing matters before CRI’s appointment.
TherapeuticsMD, Inc. reported the results of its 2025 annual meeting of stockholders held on December 15, 2025. On the October 20, 2025 record date there were 11,574,362 common shares outstanding, and 6,842,247 shares were represented, establishing a quorum.
Stockholders elected all four director nominees, each receiving about 5.1–5.2 million votes in favor. They approved, on a non-binding basis, the 2024 compensation of named executive officers with 5,162,545 votes for, 81,614 against and 8,293 abstentions. Investors also supported holding future advisory votes on executive pay every year, with 5,184,870 votes for the 1‑year frequency, and the board chose to follow this annual schedule.
Stockholders ratified Berkowitz Pollack Brant Advisors + CPAs, LLP as independent auditor for the year ending December 31, 2025, with 6,768,667 votes for. They also approved an amendment to increase authorized common stock to 640,000,000 shares, with 6,265,554 votes for, 548,884 against and 27,809 abstentions.
TherapeuticsMD, Inc. furnished an 8-K announcing it issued a press release with financial results for the quarter ended September 30, 2025. The press release is provided as Exhibit 99.1 and the disclosure appears under Item 7.01, with Item 2.02 incorporating that information by reference.
The company notes the information is furnished, not filed, under the Exchange Act. The common stock trades on Nasdaq under the symbol TXMD.
TherapeuticsMD (TXMD)8,500 restricted stock units (RSUs) on November 3, 2025.
Each RSU represents the right to receive one share of common stock and will vest on November 3, 2028. Following the grant, 8,500 derivative securities were beneficially owned on a direct basis.
TherapeuticsMD (TXMD) director Gail K. Naughton reported the acquisition of 8,500 restricted stock units (RSUs) on November 3, 2025, according to a Form 4 filing. Each RSU represents a right to receive one share of common stock. The RSUs carry a stated price of $0 and are scheduled to vest on November 3, 2028.
Following the transaction, 8,500 derivative securities are shown as beneficially owned in direct form. This reflects a standard equity award to a board member and does not involve an immediate cash transaction.
TherapeuticsMD (TXMD) — Form 4 filing: Director Cooper C. Collins reported an award of 8,500 restricted stock units on November 3, 2025. Each RSU represents the right to receive one share of common stock and carries a price of $0.
The RSUs will vest on November 3, 2028. Following this grant, 8,500 derivative securities are reported as beneficially owned, held directly.
TherapeuticsMD (TXMD) reported an insider equity award: Chief Executive Officer Marlan D. Walker filed a Form 4 disclosing the acquisition of 67,492 non-qualified stock options on 11/03/2025.
The options carry an exercise price of $1.15 per share, are exercisable on 11/03/2025, and expire on 11/03/2035. Each option is exercisable for one share of common stock, for a total of 67,492 underlying shares. The filing lists a derivative price of $0, indicating no cash paid for the grant itself.
Following the reported transaction, Walker beneficially owned 67,492 derivative securities, held with direct (D) ownership. The filing notes the underlying shares vested on November 3, 2025.
TherapeuticsMD, Inc. will hold a virtual annual meeting on December 15, 2025 to vote on six items, including an amendment to increase authorized common stock to 640,000,000 shares.
Stockholders will also vote to elect four directors, approve on a non-binding basis the compensation of named executive officers, choose the frequency of future say‑on‑pay votes, and ratify Berkowitz Pollack Brant as independent auditor for 2025. If proxies are returned without instructions, votes will be cast “for” each director nominee, “for” say‑on‑pay, “one year” for say‑on‑frequency, “for” the auditor, and “for” the charter amendment. Brokers may use discretion on the auditor ratification and the charter amendment, which are treated as “routine.”
The meeting is accessible at www.proxydocs.com/TXMD. The record date is October 20, 2025, when 11,574,362 shares of common stock were outstanding. The Board states all four current directors are independent under Nasdaq rules.
TherapeuticsMD, Inc. called a virtual annual meeting for December 15, 2025 at 8:00 a.m. ET to elect four directors and hold advisory votes on executive pay and the frequency of future pay votes, ratify the independent auditor, and consider a major charter change. The company seeks stockholder approval to increase authorized common shares to 640,000,000.
Stockholders of record at the close of business on October 20, 2025 may vote. 11,574,362 shares of common stock were outstanding as of that date. The board recommends “for” on all management proposals, including auditor ratification of Berkowitz Pollack Brant for fiscal year 2025 and an annual say‑on‑pay frequency.
Governance highlights include a fully independent four‑member board, separate Chair and CEO roles, active Audit and Compensation Committees, and policies covering clawbacks, insider trading, and anti‑hedging/pledging. 2024 CEO compensation totaled $759,174, including $500,000 salary and a $250,000 incentive payout.